Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment

IF 2 4区医学 Q2 SURGERY

Journal of Visceral Surgery Pub Date : 2024-04-01 DOI:10.1016/j.jviscsurg.2023.06.004

Gerd Jomrich , Maximilian Gruber , Elisabeth S. Gruber , Jakob Mühlbacher , Sanja Radosavljevic , Lavinia Wilfing , Daniel Winkler , Gerald Prager , Christian Reiterer , Barbara Kabon , Helmuth Haslacher , Klaus Sahora , Martin Schindl

{"title":"Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment","authors":"Gerd Jomrich , Maximilian Gruber , Elisabeth S. Gruber , Jakob Mühlbacher , Sanja Radosavljevic , Lavinia Wilfing , Daniel Winkler , Gerald Prager , Christian Reiterer , Barbara Kabon , Helmuth Haslacher , Klaus Sahora , Martin Schindl","doi":"10.1016/j.jviscsurg.2023.06.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim of the study</h3><p>Mean corpuscular volume (MCV) has shown mounting evidence as a prognostic indicator in a number of malignancies. The aim of this study was to examine the prognostic potential of pretherapeutic MCV among patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront resection or resection after neoadjuvant treatment (NT).</p></div><div><h3>Patients and methods</h3><p>Consecutive patients with PDAC who underwent pancreatic resection between 1997 and 2019 were included in this study. Neoadjuvantly treated patients’ serum MCV was measured before NT and before surgery. In patients undergoing upfront resection serum MCV was measured before surgery. Median MCV values were used as cut-off to distinguish high from low MCV values.</p></div><div><h3>Results</h3><p>Five hundred and forty-nine (438 upfront resected and 111 neoadjuvantly treated) patients were included in this study. Multivariate analysis revealed, that high MCV before and after NT, were independent negative prognostic factors for overall survival (<em>P</em>  <0.001, Wilcoxon signed-rank test) and was (<em>P</em>  <!-->0.03, Wilcoxon rank sum test) associated with tumor response to NT.</p></div><div><h3>Conclusion</h3><p>High MCV is an independent adverse prognostic factor in patients with resectable neoadjuvantly treated PDAC and may qualify as useful indicator to help physicians to provide personalized prognostication.</p></div>","PeriodicalId":49271,"journal":{"name":"Journal of Visceral Surgery","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1878788623001157/pdfft?md5=136b81cbab7dea632490fb3df598e3a2&pid=1-s2.0-S1878788623001157-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Visceral Surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878788623001157","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim of the study

Mean corpuscular volume (MCV) has shown mounting evidence as a prognostic indicator in a number of malignancies. The aim of this study was to examine the prognostic potential of pretherapeutic MCV among patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront resection or resection after neoadjuvant treatment (NT).

Patients and methods

Consecutive patients with PDAC who underwent pancreatic resection between 1997 and 2019 were included in this study. Neoadjuvantly treated patients’ serum MCV was measured before NT and before surgery. In patients undergoing upfront resection serum MCV was measured before surgery. Median MCV values were used as cut-off to distinguish high from low MCV values.

Results

Five hundred and forty-nine (438 upfront resected and 111 neoadjuvantly treated) patients were included in this study. Multivariate analysis revealed, that high MCV before and after NT, were independent negative prognostic factors for overall survival (P < 0.01, respectively). Furthermore, the median MCV value from before to after NT increased significantly (P < 0.001, Wilcoxon signed-rank test) and was (P = 0.03, Wilcoxon rank sum test) associated with tumor response to NT.

Conclusion

High MCV is an independent adverse prognostic factor in patients with resectable neoadjuvantly treated PDAC and may qualify as useful indicator to help physicians to provide personalized prognostication.

查看原文本刊更多论文

胰腺导管腺癌患者平均血球容积的预后意义及多模式治疗

研究目的平均血浆容积（MCV）作为多种恶性肿瘤的预后指标已被越来越多的证据所证明。本研究的目的是检测接受前期切除术或新辅助治疗（NT）后切除术的胰腺导管腺癌（PDAC）患者治疗前 MCV 的预后潜力。新辅助治疗患者的血清 MCV 在新辅助治疗前和手术前进行测量。接受前期切除术的患者在手术前测量血清 MCV。中位MCV值被用作区分高MCV值和低MCV值的临界值。结果这项研究共纳入了549名患者（438名前期切除患者和111名新辅助治疗患者）。多变量分析显示，新辅助治疗前和新辅助治疗后的高 MCV 值是总生存率的独立负预后因素（P 分别为 0.01）。此外，NT前后的中位MCV值显著增加（P < 0.001，Wilcoxon符号秩检验），并且与肿瘤对NT的反应相关（P = 0.03，Wilcoxon秩和检验）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Visceral Surgery SURGERY-

CiteScore

2.00

自引率

9.50%

发文量

108

审稿时长

>12 weeks

期刊介绍： The Journal of Visceral Surgery (JVS) is the online-only, English version of the French Journal de Chirurgie Viscérale. The journal focuses on clinical research and continuing education, and publishes original and review articles related to general surgery, as well as press reviews of recently published major international works. High-quality illustrations of surgical techniques, images and videos serve as support for clinical evaluation and practice optimization. JVS is indexed in the main international databases (including Medline) and is accessible worldwide through ScienceDirect and ClinicalKey.